Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.8K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.8K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.8K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.8K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

2.1K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.1K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

3.0K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
3.0K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

2.0K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
2.0K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.8K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is there an association between acute, subacute, and late genitourinary quality of life with prostate SBRT boost?

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Standardized Pipeline for Metabolism and Cognition in GO-DS21 Mouse Model: Investigating Down Syndrome Comorbidities.

Current protocols·2026
Same author

Caregiver-Associated Physical Activity Patterns, Dietary Behaviors and Interventional Beliefs in Individuals with Down Syndrome: Insights from a Large European Survey.

Nutrients·2026
Same author

Understanding Obesity in Individuals with Down Syndrome: Caregiver Perceptions, Awareness, and Motivation.

Nutrients·2026
Same author

The global scope of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA): a meta-analysis of its clinical impact, molecular epidemiology, and diagnostic challenges across 15,165 isolates.

BMC infectious diseases·2026
Same author

Radiation-Associated Internal Lymphoedema and Swallowing Impairment in Head and Neck Cancer: Insights From Imaging and Manometry.

Journal of medical imaging and radiation oncology·2026
Same journal

Editorial: Association of diabetes mellitus with cognitive impairment and neurological disorders, volume II.

Frontiers in endocrinology·2026
Same journal

Free water-mediated associations among choroid plexus enlargement, white matter lesions, and cognitive performance in type 2 diabetes mellitus.

Frontiers in endocrinology·2026
Same journal

Development and validation of a uric acid-inflammation-metabolism score for predicting osteoarthritis risk: evidence from NHANES 2007-2018 and an external Chinese cohort.

Frontiers in endocrinology·2026
Same journal

Sinonasal and skull base phosphaturic mesenchymal tumours: a case series and narrative review.

Frontiers in endocrinology·2026
Same journal

The double-edged sword effect of estrogen in kidney disease and its precision modulation.

Frontiers in endocrinology·2026
Same journal

Cholesterol, high-density lipoprotein, and glucose index as a cardiometabolic marker associated with heart rate variability and 1-year cardiovascular rehospitalization in chronic coronary syndromes with comorbid anxiety: a retrospective cohort study.

Frontiers in endocrinology·2026
See all related articles

Related Experiment Video

Updated: Mar 16, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

ACTH Antagonists.

Adrian John Clark1, Rachel Forfar2, Mashal Hussain1

  • 1Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London , London , UK.

Frontiers in Endocrinology
|August 23, 2016
PubMed
Summary
This summary is machine-generated.

Developing an adrenocorticotropin (ACTH) antagonist offers a targeted therapy for conditions like Cushing's disease and congenital adrenal hyperplasia. This approach exploits the unique specificity of the ACTH receptor (MC2R).

Keywords:
Cushing’s syndromeG protein-coupled receptoradrenocorticotropin hormonecongenital adrenal hyperplasiahigh throughput screeningpeptide hormone antagonistsreceptor antagonismreceptor modelling

More Related Videos

Primary Culture of Rat Adrenocortical Cells and Assays of Steroidogenic Functions
04:33

Primary Culture of Rat Adrenocortical Cells and Assays of Steroidogenic Functions

Published on: March 12, 2019

8.6K
Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

9.3K

Related Experiment Videos

Last Updated: Mar 16, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K
Primary Culture of Rat Adrenocortical Cells and Assays of Steroidogenic Functions
04:33

Primary Culture of Rat Adrenocortical Cells and Assays of Steroidogenic Functions

Published on: March 12, 2019

8.6K
Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

9.3K

Area of Science:

  • Endocrinology
  • Molecular Pharmacology
  • G protein-coupled receptors

Background:

  • Adrenocorticotropin (ACTH) signals through a specific G protein-coupled receptor, the melanocortin 2 receptor (MC2R).
  • MC2R function is critically dependent on the melanocortin receptor accessory protein (MRAP).
  • ACTH is the sole natural agonist for MC2R, indicating high ligand specificity.

Purpose of the Study:

  • To explore the scientific and clinical rationale for developing an ACTH antagonist.
  • To review existing and novel peptide-based antagonists for MC2R.

Main Methods:

  • Review of scientific literature on ACTH signaling and MC2R.
  • Analysis of clinical applications for MC2R antagonism.
  • Evaluation of peptide-based therapeutic candidates.

Main Results:

  • The unique specificity of the ACTH-MC2R interaction supports the development of antagonists.
  • Potential therapeutic applications include Cushing's disease, ectopic ACTH syndrome, and congenital adrenal hyperplasia.
  • Various peptides and modified peptides are being investigated as MC2R antagonists.

Conclusions:

  • Targeting the ACTH receptor with antagonists presents a promising therapeutic strategy.
  • MC2R antagonists could serve as valuable investigational tools and therapeutic agents.
  • Further research into peptide antagonists is warranted for clinical translation.